HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: Adding Daratumumab to the Frontline for Newly Diagnosed Myeloma Patients
Posted: Dec 17, 2016
Clinical Trial: Adding Daratumumab to the Frontline for Newly Diagnosed Myeloma Patients image

A new study is open at the Levine Cancer Institute (with many more sites to follow) adding daratumumab to Revlimid, Velcade and dexamethasone for newly diagnosed, transplant-eligible myeloma patients. The study will compare the "standard of care" with RVd vs. RVD plus daratumumab. Recently, daratumumab was FDA approved for treatment after one relapse with either Revlimid/dex or Velcade/dex based on data from the POLLUX and CASTOR clinical trials. Today, daratumumab is not FDA-approved for newly diagnosed patients. Investigators are now looking into earlier approaches because it looks to make standard myeloma treatments even better. Dr. Peter Voorhees from the Levine Cancer Institute shares more about this open study on Myeloma Crowd TV. To find this clinical trial, click here: Daratumumab with RVD Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube